Patty Baskin
Executive Editor, Neurology®
pbaskin@aan.com
(612) 928-6021
Exam: Exam 19
Issue: January 26, 2010
Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review)
Upon completion of this podcast, the participant will be able to:
1) List some clinical indications for treating spasticity.
2) State some treatment options for segmental and gerneralized spasticity.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
Program Accreditation and Development Subcommittee (PADS) is responsible for reviewing and evaluating all CME programs. PADS members: Pradeep K. Sahota MD, FAAN, has nothing to disclose, Allison Brashear MD, FAAN, has received personal compensation for activities with Allergan, Merz, Ipsen and Osmotica as a consultant, has received personal compensation in an editorial capacity for Wemove, has received research support from Allergan, Merz, and Ipsen, J. Clay Goodman MD, FAAN, has nothing to disclose, Steven L. Lewis MD, FAAN, has received personal compensation in an editorial capacity for the journal Neurology, Barbara F. Westmoreland MD, FAAN, has nothing to disclose, Susan Rodmyre, has nothing to disclose.
Robert A. Gross, MD, PhD, FAAN has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past five years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers’ bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology.
Ted M. Burns, MD, receives a stipend as Podcast Editor for Neurology®, performs EMG studies in his neuromuscular practice (30% effort), and received compensation for a presentation on MG-QOL15, given to study investigators of eculizumab in myasthenia gravis. AAN staff members editing the test (P Baskin, M Petrovick, K Wiersma) have no disclosures. The CME Journal Editors, who have reviewed the exam, are Steven Lewis MD, who has no disclosures, and Paul E Schulz, MD, who was formerly on the Speakers Bureau for Pfizer and Forrest. Dr. Delgado serves on the editorial board of Developmental Medicine and Child Neurology; has received research support from Abbott, Sciele Pharma, Inc., UCB, Allergan, Inc., the Hurst Foundation, the United Cerebral Palsy Research & Educational Foundation, the Linda and Don Carter Foundation, and the Crowley Carter Foundation; and estimates 50% of his clinical effort is spent on assessment and management of motor disorders of childhood, which includes treating children with cerebral palsy with oral antispasticity medications, ITB, and botulinum toxin injections. Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.
CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.
The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Neurology designates that participants will receive 0.5 AMA PRA Category 1 CME credits™ by answering the multiple-choice questions in the online Podcast quiz.
The American Academy of Neurology holds copyright for all materials in this exam.
Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.
A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.